MDxHealth SA (MDXH) - Yahoo Finance Find the latest MDxHealth SA (MDXH) stock quote, history, news and other vital information to help you with your stock trading and investing
MDxHealth (MDXH) Stock Price Overview - Stock Analysis MDxHealth SA offers a comprehensive portfolio of precision diagnostics targeting all stages of prostate cancer and advanced UTI detection, addressing a $4 9 billion TAM The company's flagship product
MDxHealth S. A. Stock Quote (U. S. : Nasdaq) - MarketWatch MDxHealth SA is a commercial-stage precision diagnostics company, which engages in the development and commercialization of molecular diagnostic products for personalized cancer treatment It
Login | MDX Client Portal Forgot Password? You are using an older browser If you wish to take full advantage of this site please upgrade to a modern browser
MDxHealth (MDXH) Earnings Date and Reports 2025 - MarketBeat MDxHealth has not confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, August 14th, 2025 based off last year's report dates Learn more on MDXH's earnings history What guidance has MDxHealth issued on next quarter's earnings? MDxHealth issued an
Press Releases - mdxhealth Mdxhealth Announces Fourth Quarter and Full-Year 2023 Financial Results 2023 revenue grew by 89% to $70 2 million; excluding GPS, revenues up 42%2023 gross margin expanded
MDxHealth, Inc, 15279 Alton Pkwy, Irvine, CA 92618, US - MapQuest MDXHEALTH, INC is a leading molecular diagnostic company based in Irvine, CA, specializing in personalized solutions for the earlier detection of aggressive prostate cancer and urologic diseases
MDxHealth Reports Q1-2024 Results and Announces Growth Capital from . . . IRVINE, CA, and HERSTAL, BELGIUM – May 1, 2024 (GlobeNewswire) – MDxHealth SA (NASDAQ: MDXH) (the “Company” or “mdxhealth”), a commercial-stage precision diagnostics company, today announced its financial results for the first quarter ended March 31, 2024 and the closing of a new debt facility with OrbiMed